Suppr超能文献

评估抗 rh-GAA 在意大利 GSDII 研究组晚发性庞贝病队列中的 ERT 反应调节作用。

Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.

机构信息

Center for Neuromuscular Diseases, Unit of Neurology, ASST Spedali Civili and University of Brescia, Brescia, Italy.

Emergency Neurology, IRCCS Mondino Foundation, Pavia, Italy.

出版信息

Adv Ther. 2019 May;36(5):1177-1189. doi: 10.1007/s12325-019-00926-5. Epub 2019 Mar 16.

Abstract

INTRODUCTION

Patients with late-onset Pompe disease (LOPD) receiving enzyme replacement therapy (ERT) may develop IgG antibodies against alglucosidase alpha (anti-rhGAA) in the first 3 months of treatment. The exact role of these antibodies in modulating efficacy of ERT in this group of patients is still not fully understood. To assess whether anti rh-GAA antibodies interfere with ERT efficacy, we studied a large Italian cohort of LOPD patients.

METHODS

We analyzed clinical findings and performed serial measurements of IgG anti rh-GAA antibody titers from 64 LOPD patients treated with ERT. The first examination (T0) was completed on average at 17.56 months after starting ERT, while the follow-up (T1) was collected on average at 38.5 months. Differences in T0-T1 delta of the six-minute walking test (6MWT), MRC sum score (MRC), gait, stairs and chair performance (GSGC) and forced vital capacity (FVC) were considered and then related to the antibody titers.

RESULTS

Almost 22% of the patients never developed antibodies against GAA, while 78.1% had a positive titer (31.2% patients developed a low titer, 43.8% a medium titer and 3.1% a high titer). No statistical significance was found in relating the T0-T1 delta differences and antibody titers, except for MRC sum score values in a subgroup of patients treated < 36 months, in which those with a null antibody titer showed a greater clinical improvement than patients with a positive titer.

CONCLUSION

Our results confirm that in a large cohort of LOPD patients, anti rh-GAA antibody generation did not significantly affect either clinical outcome or ERT efficacy. However, in the first 36 months of treatment, a possible interference of low-medium antibody titers with the clinical status could be present. Therefore, a careful and regular evaluation of antibody titers, especially in cases with evidence of clinical decline despite ERT, should be performed.

摘要

简介

接受酶替代疗法(ERT)的迟发性庞贝病(LOPD)患者在治疗的头 3 个月内可能会产生针对阿尔法葡糖苷酶(抗-rhGAA)的 IgG 抗体。这些抗体在调节该组患者 ERT 疗效中的确切作用尚不完全清楚。为了评估抗 rh-GAA 抗体是否干扰 ERT 疗效,我们研究了一个大型意大利 LOPD 患者队列。

方法

我们分析了 64 名接受 ERT 治疗的 LOPD 患者的临床发现,并对 IgG 抗 rh-GAA 抗体滴度进行了连续测量。第一次检查(T0)在开始 ERT 后平均 17.56 个月完成,而随访(T1)在平均 38.5 个月收集。考虑了 6 分钟步行试验(6MWT)、MRC 总和评分(MRC)、步态、楼梯和椅子表现(GSGC)和用力肺活量(FVC)的 T0-T1 差值的差异,然后将其与抗体滴度相关联。

结果

几乎 22%的患者从未产生过针对 GAA 的抗体,而 78.1%的患者产生了阳性滴度(31.2%的患者产生低滴度,43.8%的患者产生中滴度,3.1%的患者产生高滴度)。除了在治疗<36 个月的患者亚组中 MRC 总和评分值外,未发现 T0-T1 差值差异与抗体滴度相关,在该亚组中,无抗体滴度的患者比有阳性滴度的患者显示出更大的临床改善。

结论

我们的结果证实,在一个大型 LOPD 患者队列中,抗 rh-GAA 抗体的产生并没有显著影响临床结局或 ERT 疗效。然而,在治疗的头 36 个月内,低-中抗体滴度可能会对临床状况产生干扰。因此,应特别在 ERT 治疗后有临床恶化证据的情况下,定期仔细评估抗体滴度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验